User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

about

The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.

P2860

Q39140294-2AA5601B-071D-4BE8-A991-53324BA89C4F Q51246605-C27B9BE9-D00C-4A54-ABD6-86228FC81E7E

P2860

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

Item

http://www.wikidata.org/entity/Q38587097

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

@en

type

Item

label

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

@en

prefLabel

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

@en

P1476

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

@en

P2093

Charles F Shaefer

http://www.w3.org/2001/XMLSchema#string

Pamela Kushner

http://www.w3.org/2001/XMLSchema#string

Richard Aguilar

http://www.w3.org/2001/XMLSchema#string

P2860

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review

Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015

Biology of incretins: GLP-1 and GIP

LEADER 3--lipase and amylase activity in subjects with type 2 diabetes: baseline data from over 9000 subjects in the LEADER Trial.

Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes.

Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability

P304

818-826

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/00325481.2015.1090295

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26371721

http://www.w3.org/2001/XMLSchema#string

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

about

P2860

P2860

User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698